AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by research analysts at Shore Capital in a report issued on Monday, ThisIsMoney.Co.Uk reports.
Other equities analysts have also recently issued research reports about the stock. Deutsche Bank reaffirmed a “buy” rating and set a GBX 8,300 ($102.14) price target on shares of AstraZeneca in a research report on Tuesday, April 14th. Liberum Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Friday, May 29th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, July 21st. Oddo Securities cut shares of AstraZeneca to a “reduce” rating and reduced their price target for the stock from GBX 8,100 ($99.68) to GBX 7,600 ($93.53) in a research report on Monday, June 22nd. Finally, Jefferies Financial Group reissued a “hold” rating on shares of AstraZeneca in a report on Thursday, July 9th. Six analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of GBX 8,336.67 ($102.59).
Shares of AZN stock opened at GBX 8,700 ($107.06) on Monday. The company has a debt-to-equity ratio of 171.72, a quick ratio of 0.56 and a current ratio of 0.75. AstraZeneca has a one year low of GBX 83.80 ($1.03) and a one year high of GBX 9,537.09 ($117.37). The company’s 50-day simple moving average is GBX 8,558.96 and its 200-day simple moving average is GBX 7,923. The stock has a market capitalization of $114.17 billion and a price-to-earnings ratio of 75.19.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Technical Analysis
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.